A Conformationally Restricted β-Strand HIV Protease Inhibitor

Area of Science:

• Medicinal Chemistry
• Organic Chemistry
• Structural Biology

Background:

• Cyclopropanes are valuable as conformationally restricted subunits in biological systems.
• Pseudopeptides incorporating cyclopropanes can restrict side-chain orientation and enforce backbone secondary structures.
• HIV protease inhibitors are crucial in treating HIV/AIDS.

Purpose of the Study:

• To synthesize and evaluate a novel cyclopropane-containing pseudopeptide analog of an HIV protease inhibitor.
• To assess the efficacy of cyclopropane subunits in restricting conformation and mimicking peptide backbone structures.
• To compare the enzyme inhibition constants of the cyclopropane analog with the parent inhibitor.

Main Methods:

• Design and synthesis of a cyclopropane-containing pseudopeptide analog (compound 1) based on a known HIV protease inhibitor (compound 2).
• Modeling of the analog to mimic the "extended" backbone conformation observed in the parent inhibitor.
• Enzyme inhibition assays to determine and compare inhibition constants (Ki) for compound 1 and compound 2.

Main Results:

• The cyclopropane-containing analog was successfully synthesized.
• The analog was designed to restrict valine residue orientation and mimic the beta-strand conformation.
• Enzyme inhibition constants will be compared to elucidate the cyclopropane's efficacy.

Conclusions:

• Cyclopropane subunits show promise for restricting peptide conformation in drug design.
• This approach can lead to novel pseudopeptides with potential therapeutic applications, such as improved HIV protease inhibitors.
• Further studies are warranted to fully explore the utility of cyclopropane-modified pseudopeptides.